Funding Secured: $35 Million Series B Round Successfully Completed for Further Development of the FieldForce Pulsed Field Ablation Technology
Field Medical, a clinical-stage company specialising in pulsed field ablation (PFA) technology, has announced a successful $35 million Series B funding round. This investment reinforces the momentum behind the company and positions it to advance towards pivotal trial readiness in the treatment of ventricular tachycardia (VT), a complex and underaddressed cardiac arrhythmia.
The funding will be utilised primarily for the initiation of the company's pivotal VERITAS trial, the advancement of the FieldForce Ablation System, and the enhancement of Field Medical's clinical and regulatory capabilities. Additionally, the funds will scale research and development efforts and clinical operations to optimise the FieldForce platform.
Steven Mickelsen, MD, the Founder and CEO of Field Medical, stated that ventricular tachycardia is an underpenetrated segment in electrophysiology with a lack of necessary tools.However, the company is poised to unlock this opportunity with its next-generation therapy. Louis Cannon, MD, founder and senior managing director of BioStar Capital, expressed support for Field Medical's transformative technology tackling a difficult challenge in cardiology with real innovation and urgency.
The strong pilot data presented at the 2025 Heart Rhythm Society meeting contributed to this raise, reflecting confidence in the technology's promise for treating VT. The company plans to leverage this funding to bring next-generation PFA therapy to the VT market, aiming to provide a treatment built for speed, precision, and significant clinical progress.
The Series B round was chaired by Mark Wisniewski, CFO of Enterra Medical, and includes Marlou Janssen, an experienced executive and board member, formerly President of Biotronik U.S. and VP/GM at EPD Solutions Philips, and Ben Cannon, a Founding Partner at Cue Growth, offering institutional governance expertise to Field Medical.
Alexei Mlodinow, MD, MBA, a surgeon, serial entrepreneur, and investor with a track record in medtech innovation, is also involved in the company. The strong showing at the Heart Rhythm Society meeting attracted institutional investor interest and reinforced continued support from existing investors, indicating confidence in Field Medical's technology, strategy, and leadership.
With this funding, Field Medical has now raised $75 million, reinforcing its leadership in PFA innovation for complex arrhythmias. The company views VT treatment as an unmet clinical need that could mirror the early growth and impact of PFA technology in atrial fibrillation care. The Series B round positions Field Medical to advance toward pivotal trial readiness and ultimately redefine treatment options for high-risk VT patients.
- The funding secured by Field Medical will be predominantly used for the advancement of the FieldForce Ablation System, the initiation of the pivotal VERITAS trial, and the enhancement of Field Medical's clinical and regulatory capabilities, aiming to provide a treatment for ventricular tachycardia (VT) built for speed, precision, and significant clinical progress.
- The investment will also scale research and development efforts and clinical operations to optimise the FieldForce platform, reflecting the confidence in the technology's promise for treating VT, as demonstrated by the strong pilot data presented at the 2025 Heart Rhythm Society meeting.
- With the Series B funding round, Field Medical has now raised a total of $75 million, attracting institutional investor interest and reinforcing continued support from existing investors, indicating their confidence in Field Medical's technology, strategy, and leadership, and positioning the company to redefine treatment options for high-risk VT patients. This investment also opens up opportunities for innovation in other fields such as health and wellness, finance, business, and technology, with the company poised to unlock underpenetrated segments like electrophysiology with its next-generation therapy.
